Objective To explore the effect and mechanism of alendronate in Systemic lupus erythematosus( SLE)patients of hormone maintenance phase. Method 60 cases of hormone maintenance phase SLE women patients( prednisone 5~15 mg/d) were divided into treatment group and control group randomly. The control group were treated with a table of Caltrate D 600 per day. The treatment group were treated with a table of Caltrate D 600 per day plus alendronate(70 mg)per week. The bone miner-al density(BMD),blood calcium and phosphorus,Crossl procollagen type Ⅰ carboxytermina(β-Crosslaps),serum osteoprote-gerin were detected at starting point and after 6 months treatment. Results After 6 months treatment,the lumbar spine and femoral neck BMD,serum osteoprotegerin of two groups increased than before,The treatment group was higher than that of control group (P﹤0. 05).β-Crosslaps were delined in treatment group(P﹤0. 05). There was no significant difference between two groups in blood calcium and phosphorus( P﹥0. 05 ). Conclusion Alendronate can increase the BMD of SLE patients of hormone mainte-nance phase.%目的：探讨阿仑膦酸钠对系统性红斑狼疮（ SLE）患者激素维持期骨量丢失的临床疗效及作用机制。方法：60例激素维持期SLE女性患者（强的松5~15 mg/d），随机分为治疗组和对照组各30例，均每天给予钙尔奇D600mg治疗，治疗组同时加服阿仑膦酸钠70 mg/周，共6个月。在治疗前后分别测定两组患者的腰椎和股骨颈的骨密度（BMD）、血Ca2＋、血P3＋、Ⅰ型胶原羧基末端肽（β-Crosslaps）及血清骨钙素（OPG）等。结果：治疗6个月后，治疗组腰椎和股骨颈的骨密度、血清OPG均较治疗前增加，β-Crosslaps较前降低，差异有统计学意义（ P﹤0.05），对照组治疗前后比较，差异无统计学意义（ P﹥0.05），两组血Ca2＋、血P3＋与治疗前比较，差异无统计学意义（ P﹥0.05）。结论：阿仑膦酸钠能增加SLE患者激素维持期的骨密度，有很好的骨保护作用。
展开▼
